Read/Post Comments (0) | Recommended this article (0)
Please login to Zacks.com or register to post a comment.
Zacks' 7 Best Stocks
for July, 2013
FREE Report for Zacks.com
Visitors Only
Visitors Only
They're hand-picked from the list of Zacks Rank #1 Strong Buys. Our experts predict that their prices will jump the soonest.
Today, you can see them free.
- Latest News
- Most Popular
- How to Invest in QE's Twilight
- RTI: Fed Keeps QE Pace Unchanged
- ETFs on the Move After Bernanke's Press Conference
- Roundtable Top Picks of the Week
- FED Front & Center Again
- RTI: Sector Strength Charts - Where's the Opportunity Now?
- Surging Financial ETFs Beating the Market
- Utility Industry Stock Outlook - June 2013
- Your Next Stock Should Be Making New Highs
- AWS 6/19: Will Bernanke Clarify Matters Today?
- PFP 6/19: Investors Bold in Wake of the Fed
Recent Quotes
| No Recent Quote currently available |
My Portfolio
|
My Portfolio Tracker One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts. Set yours up today. |
More Zacks Resources
Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.
Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.
Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.
My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.
Zacks #1 Stocks on the Move 06/19/2013
| Company Name | Symbol | %Change |
|---|---|---|
| SONIC FOUNDR | SOFO | 4.40% |
| SUPPORTCOM I | SPRT | 3.75% |
| UNISYS CORP | UIS | 3.31% |
| SHORETEL INC | SHOR | 3.22% |
| GREEN MOUNTA | GMCR | 3.13% |
Quick Links
Resources
Client Support
Zacks Research is Reported On:
Zacks Investment Research
is an A+ Rated BBB
Accredited Business.
Copyright 2013 Zacks Investment Research
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1986 it has nearly tripled the S&P 500 with an average gain of +26% per year. These returns cover a period from 1986-2011 and were examined and attested by Baker Tilly, an independent accounting firm.
Visit performance for information about the performance numbers displayed above.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This page is temporarily not available. Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext. 9339.
SurModics Inc.’s (SRDX - Analyst Report) third quarter fiscal 2012 earnings from continued operations (excluding special items) of 17 cents per share were above the Zacks Consensus Estimate of 13 cents. The company earned 12 cents per share on an adjusted basis in the year-ago quarter. Higher year-over-year earnings were primarily attributable to increased adjusted revenues.
Adjusted revenues climbed 17.5% year over year to $13.7 million in the reported quarter, edging past the Zacks Consensus Estimate of $13 million. Revenues on a reported basis (including special items) were up 7.4% to approximately $14 million in the third quarter of fiscal 2012.
Revenues at SurModics climbed up due to increased sales from vitro diagnostics and hydrophilic coatings. However, this was partly offset by a decline in royalty revenues from Johnson & Johnson (JNJ - Analyst Report) pertaining to Cypher and Cypher Select Plus drug eluting stents. Johnson & Johnson stopped manufacturing these products from the end of calendar year 2011.
For the reported quarter, royalties and license fees accounted for approximately 50.2% of total adjusted revenue with product sales and research & development accounting for 41.7% and 8.1%, respectively.
Following the November 2011 sale of the assets of its Pharmaceuticals division to Germany’s Evonik Industries AG, SurModics currently operates through two business units: Medical Devices and In Vitro Diagnostics.
SurModics’ reported revenues from the Medical Devices segment were approximately $10.3 million, up 7.4%. Growth was attributable to an increase in sales of hydrophilic coatings and newly launched customer products.
Reported revenues from the In Vitro Diagnostics unit increased 7.3% to $3.7 million.
In addition to announcing financial results, SurModics stated that a $55 million share buyback program has been authorized by its Board of Directors. We believe that the buyback program highlights the company’s commitment to create value for shareholders.
Our Recommendation
We currently have a Neutral recommendation on SurModics. The stock carries a Zacks #3 Rank (short-term Hold rating).
Get the full Analyst Report on SRDX - FREE
Get the full Analyst Report on JNJ - FREE